摘要
目的观察利伐沙班对非瓣膜性房颤患者抗凝效果及安全性,为临床合理选择用药提供依据。方法选择我院2015年3月—2017年7月收治的非瓣膜性房颤患者88例作为研究对象。将其随机分为华法林组和利伐沙班组,每组各44例。两组患者分别采用华法林和利伐沙班进行治疗,比较两组患者栓塞事件和出血事件发生率。结果利伐沙班组出血事件发生率(6.82%vs.20.45%)以及栓塞事件发生率(9.09%vs.25.00%)均低于华法林组,差异均具有统计学意义(P<0.05)。结论利伐沙班治疗非瓣膜性房颤患者可以取得良好的临床疗效,安全性好。
Objective To observe the effect and safety of Shaaban on anticoagulation in patients with non-valvular atrial fibrillation, and to provide evidence for rational selection of drugs. Methods 88 patients with non-valvular atrial fibrillation treated in our hospital from March 2015 to July 2017 were selected as the research subjects. They were randomly divided into warfarin group and rivaroxaban group, 44 cases in each group. The two groups were treated with warfarin and rivaroxaban respectively. The incidence of embolic events and bleeding events were compared between the two groups after treatment. Results The incidence of bleeding events in the rivaroxaban group （6.82% vs. 20.45%） and the incidence of thromboembolic events （9.09% vs. 25.00%） were lower than the warfarin group, the differences were statistically significant （P 〈 0.05）. Conclusion The treatment of non- valvular atrial fibrillation patients with rivaroxaban has good clinical efficacy and good safety.
出处
《中国继续医学教育》
2017年第29期96-97,共2页
China Continuing Medical Education
关键词
利伐沙班
非瓣膜性房颤
临床疗效
安全性
rivaroxaban
non-valvular atrial fibrillation
clinical efficacy
safety
